In a related systemic study, Koufaris et al. [43] have revealed that in breast cancer there existed three target genes of miR-22 including ACLY, which participate in different metabolic pathways such as de novo lipogenesis, fatty acid elongation and mitochondrial one-carbon metabolism. This evidence concerns the gene ACLY and breast cancer.